HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by PELLETIER, R. Articles by DE CAROLIS, E. Search for Related Content PubMed PubMed Citation Articles by PELLETIER, R. Articles by DE CAROLIS, E. Agricola Articles by PELLETIER, R. Articles by DE CAROLIS, E.

Voriconazole and fluconazole susceptibility of Candida isolates

Laboratoire de Microbiologie, L'Hôtel-Dieu de Québec du Centre Hospitalier Universitaire de Québec, Québec and *Anti-Infectives Research and Development Group, Pfizer Canada, Kirkland, Québec, Canada

Corresponding author: Dr R. Pelletier (e-mail: rene.pelletier{at}chuq.qc.ca).

Received 27 June 2001; revised version accepted 21 Nov. 2001.

Abstract

An adapted NCCLS M27-A method was used to evaluate the activity of voriconazole (VRC) and fluconazole (FLC) against 295 Candida isolates collected from 189 patients (including isolates from deep sites). Isolates included 186 C. albicans, 54 C. glabrata, 27 C. tropicalis, 14 C. parapsilosis, 6 C. krusei, 6 C. lusitaniae, 1 C. lypolytica and 1 C. sake. Forty-two isolates had reduced susceptibility to FLC (MIC >8 mg/L); 83.3% of these had VRC MICs 2 mg/L (9 of 11 C. albicans, 18 of 19 C. glabrata, 6 of 6 C. krusei, 2 of 2 C. lusitaniae and 0 of 4 C. tropicalis), including 60% of isolates collected from deep-seated infections. These results suggested that in the era of azole resistance, VRC has a promising antifungal activity for serious infections with Candida spp., including most species with low susceptibility to FLC and uncommonly isolated species.

This article has been cited by other articles:

				M. A. Pfaller, D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A Ghannoum, F. C. Odds, M. G. Rinaldi, et al. Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints. J. Clin. Microbiol., March 1, 2006; 44(3): 819 - 826. [Abstract] [Full Text] [PDF]

				J. Bagg, M P. Sweeney, A. N Davies, M. S Jackson, and S. Brailsford Voriconazole susceptibility of yeasts isolated from the mouths of patients with advanced cancer J. Med. Microbiol., October 1, 2005; 54(10): 959 - 964. [Abstract] [Full Text] [PDF]